News >

Targeting Tumor Vasculature in Ovarian Cancer

Angelica Welch
Published: Wednesday, Dec 27, 2017

We did a series of experiments, including wound-disruption studies. We targeted the endothelial cells and we got these from our patients intraoperatively. What we found was that there was a series of factors that seemed to drive tumor angiogenesis, which are missing from normal angiogenesis. We have been in the process of trying to come up with a therapeutic targeting strategy for that specific factor. We know that these are relevant, and we are really excited at the possibility of coming up with a tumor angiogenesis drug that won't affect wound healing. 


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x